@rheumnow abs1329 Pooled safety data FINCH1-3 Ph3 trials on Filgotinib showed favorable safety profile FIL mono & in combination w/cDMARDs: incidences of MACE 0.2% for FIL, 0.3%adalimumab (ADA), and 0.5% PBO/csDMARD. Incidences of DVT/PE < 0.1% for FIL, 0% ADA& 0.3% PBO/csDMARD https://t.co/NhC6cWplGu